Home Cart 0 Sign in  

[ CAS No. 134523-00-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 134523-00-5
Chemical Structure| 134523-00-5
Structure of 134523-00-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 134523-00-5 ]

Related Doc. of [ 134523-00-5 ]

Alternatived Products of [ 134523-00-5 ]

Product Details of [ 134523-00-5 ]

CAS No. :134523-00-5 MDL No. :MFCD00899261
Formula : C33H35FN2O5 Boiling Point : -
Linear Structure Formula :- InChI Key :XUKUURHRXDUEBC-KAYWLYCHSA-N
M.W : 558.64 Pubchem ID :60823
Synonyms :

Calculated chemistry of [ 134523-00-5 ]

Physicochemical Properties

Num. heavy atoms : 41
Num. arom. heavy atoms : 23
Fraction Csp3 : 0.27
Num. rotatable bonds : 13
Num. H-bond acceptors : 6.0
Num. H-bond donors : 4.0
Molar Refractivity : 158.26
TPSA : 111.79 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.19 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.58
Log Po/w (XLOGP3) : 4.96
Log Po/w (WLOGP) : 6.54
Log Po/w (MLOGP) : 3.48
Log Po/w (SILICOS-IT) : 6.15
Consensus Log Po/w : 4.94

Druglikeness

Lipinski : 1.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -5.99
Solubility : 0.000578 mg/ml ; 0.00000103 mol/l
Class : Moderately soluble
Log S (Ali) : -7.05
Solubility : 0.0000503 mg/ml ; 0.00000009 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -9.13
Solubility : 0.000000417 mg/ml ; 0.0000000007 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 3.0
Synthetic accessibility : 4.95

Safety of [ 134523-00-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 134523-00-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 134523-00-5 ]
  • Downstream synthetic route of [ 134523-00-5 ]

[ 134523-00-5 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 134523-00-5 ]
  • [ 125995-03-1 ]
YieldReaction ConditionsOperation in experiment
46% at 60℃; for 40 h; Example 1
Synthesis of Atorvastatin Lactone
5.0 g (8.6 mmole) of atorvastatin calcium was dissolved in 300 mL ethyl acetate and washed with 300 mL 10percent (w/v) aqueous sodium hydrogen sulfate solution (pH 3).
The organic phase was dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure to afford 2.85 g (5.11 mmole) of atorvastatin acid.
This material was dissolved in 300 mL anhydrous toluene and heated at 60° C. for 40 hours, at which time analytical thin-layer chromatography using 4:1 methylene chloride:acetone eluent indicated near-complete conversion of the starting acid to a less polar product.
The toluene was removed under reduced pressure and the reaction mixture was fractionated on 300 cc of silica gel using 4:1 methylene chloride:
acetone eluent to afford, after combining, concentrating and drying of the appropriate fractions, 2.14 g (3.96 mmol, 46percent overall) of atorvastatin lactone as a white foam.
The 400 MHz 1H nuclear magnetic resonance (NMR) spectrum and the electrospray mass spectrum (ES-MS) were consistent with the lactone product. 1H NMR (Me2SO-d6) δ 9.80 (s, 1H), 7.49 (d, 2H), 7.25-7.15 (m, 6H), 7.05 (s, 4H), 6.99 (t, 2H), 5.15 (d, 1H), 4.46 (br s, 1H), 4.02 (s, 1H), 3.97 (m, 1H), 3.89 (m, 1H), 3.21 (q, 1H), 2.55 (dd, 1H), 2.32 (dd, 1H), 1.74 (br s, 2H), 1.6 (m, 2H), 1.36 (d, 6H). ES-MS: obsvd. m/z 541 ([MH]+).
Reference: [1] Patent: US2005/261354, 2005, A1, . Location in patent: Page/Page column 52
[2] Patent: WO2004/14896, 2004, A1, . Location in patent: Page 9; 16
[3] Patent: WO2007/29216, 2007, A1, . Location in patent: Page/Page column 6-9; 11
[4] Collection of Czechoslovak Chemical Communications, 2008, vol. 73, # 2, p. 229 - 246
  • 2
  • [ 67-56-1 ]
  • [ 134523-00-5 ]
  • [ 125995-03-1 ]
  • [ 345891-62-5 ]
Reference: [1] British Journal of Pharmacology, 2001, vol. 132, # 6, p. 1183 - 1192
Same Skeleton Products
Historical Records